FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine Post author:PacConAdmin Post published:July 15, 2025 Post category:Uncategorized Post comments:0 Comments FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine Source: FDA Press Releases Tags: aaps Read more articles Previous PostFDA Approves Gardenia (Genipin) Blue Color Additive While Encouraging Faster Phase-Out of FD&C Red No. 3 Next PostFDA to Revoke 52 Obsolete Standards of Identity for Food Products You Might Also Like FDA OCP Seeks Public Input on Drug Development Clinical Pharmacology Programs April 25, 2024 FTC Rips PBM Consolidation, Ability to “Squeeze” Smaller Pharmacies in Interim Report July 9, 2024 First OTC Continuous Glucose Monitor Cleared by the FDA March 6, 2024 Leave a Reply Cancel replyCommentEnter your name or username to comment Enter your email address to comment Enter your website URL (optional) Save my name, email, and website in this browser for the next time I comment.